Acute myeloid leukemia with mutated NPM1: Diagnosis, prognosis and therapeutic perspectives

Current Opinion in Oncology

Volumn 21, Issue 6, 2009, Pages 573-581

  Falini, Brunangelo ^a   Sportoletti, Paolo ^a   Martelli, Maria Paola ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Acute myeloid leukemia; Antibodies; Normal karyotype; Npm1 mutations; Nucleophosmin

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; ETOPOSIDE; IDARUBICIN; LEPTOMYCIN B; NUCLEOPHOSMIN; RETINOIC ACID; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TRANSPORT; REVIEW; WESTERN BLOTTING; WORLD HEALTH ORGANIZATION; ACUTE DISEASE; GENETIC PREDISPOSITION; GENETICS; MOLECULAR GENETICS; MUTATION; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE;

ACUTE DISEASE; BASE SEQUENCE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; PROGNOSIS;

EID: 74049158596     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283313dfa     Document Type: Review

References (85)

1. Arber D, Brunnlng RD, Le Beau MM, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 110-123.
2. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109:431-448.
3. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352:254-266. (Pubitemid 40110814)
4. Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia carrying cytoplasmlc/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007; 109:874-885. This is a comprehensive review of biological and clinical features of AML with cytoplasmlc/mutated NPM1 (NPMc- AML).
5. Liso A, Bogliolo A, Freschi V, et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML Leukemia 2008; 22:1285-1289.
6. Martelli MP, Manes N, Pettirossi V, et al. Absence of nucleophosmin leukaemlc mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc + AML. Leukemia 2008; 22:195-198.
7. Facchetti F, Pileri SA, Agostinelli C, et al. Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Haematologica 2009; 94:285-288.
8. Falini B, Mecucci C, Saglio G, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 2008; 93:439-442.
9. Haferlach C, Mecucci C,Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biological, pathological, immunophenotypic, and prognostic features. Blood 2009. [Epub ahead of print]
10. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107:4011-4020.
11. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111:2776-2784.
12. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc | AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005; 106:899-902. (Pubitemid 41076430)
13. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106:3747-3754.
14. Mullighan CG, Kennedy A, Zhou X, et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 2007; 21:2000-2009. (Pubitemid 47299976)
15. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008; 105:3945-3950. (Pubitemid 351723504)
16. Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111:5078-5085.
17. Bolli N, De Marco MF, Martelli MP, et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia 2009; 23:501-509.
18. Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1 : molecular basis and clinical implications. Leukemia 2009. [Epub ahead of print]
19. Falini B, Martelli MP, Mecucci C, et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008; 93:775779. (Pubitemid 351669321)
20. Meloni G, Mancini M, Gianfelici V, et al. Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. Haematologica 2009; 94:298-300.
21. Palmisano M, Grafone T, Ottaviani E, et al. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Haematologica 2007; 92:1268-1269.
22. Papadaki C, Dufour A, Seibl M, et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009; 144:51 7-523.
23. Schnittger S, Schoch C, Kern W, et al. Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML Blood 2009. [Epub ahead of print].
24. Bonetti P, Davoli T, Sironl C, et al. Nucleophosmin and its AML-associated mutant regulate c-myc turnover through Fbw7 gamma. J Cell Biol 2008; 182:19-26. (Pubitemid 352008617)
25. Di Fiore PP. Playing both sides: nucleophosmin between tumor suppression and oncogenesis. J Cell Biol 2008; 182:7-9.
26. Colombo E, Bonetti P, Lazzerini Denchi E, et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 2005; 25:88748886. (Pubitemid 41429079)
27. den Besten W, Kuo ML, Williams RT, et al. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 2005; 4:15931598.
28. Sportoletti P, Grisendi S, Majid SM, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008; 111:3859-3862.
29. Pasqualucci L, Li S, Meloni G, et al. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V61 7F+ primary myelofibrosis: de-novo origin? Leukemia 2008; 22:1459-1463.
30. Shiseki M, Kitagawa Y, Wang YH, et al. Lack of nucleophosmin mutation in patients with myelodysplastlc syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Leuk Lymphoma 2007; 48:2141-2144. (Pubitemid 350091055)
31. Falini B. Any role for the nucleophosmin (NPM1) gene in myelodysplastlc syndromes and acute myeloid leukemia with chromosome 5 abnormalities? Leuk Lymphoma 2007; 48:2093-2095.
32. Piccaluga PP, Sabattini E, Bacci F, et al. Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. Leukemia 2009; 23:1370-1371.
33. Andersen MT, Andersen MK, Christiansen DH, et al. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features. Leukemia 2008; 22:951-955. (Pubitemid 351689876)
34. Falini B. Therapy-related acute myeloid leukaemia with mutated NPM1 : treatment induced or de novo in origin? Leukemia 2008; 22:891-892.
35. Cazzaniga G, Lo Nigro L, Cifola I, et al. Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. Leukemia 2009; 23:199-203.
36. Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005; 106:1419-1422. (Pubitemid 41129610)
37. Brown P, Mclntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007; 110:979985. (Pubitemid 47267437)
38. Thiede C, Creutzig E, Reinhardt D, et al. Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1 -exon 12. Leukemia 2007; 21:366-367. (Pubitemid 46158137)
39. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106:2854-2861. (Pubitemid 41510764)
40. Yan L, Chen S, Liang J, et al. Analysis of NPM1 gene mutations in Chinese adults with acute myeloid leukemia. Int J Hematol 2007; 86:143-146.
41. Shimada A, Taki T, Kubota C, et al. No nucleophosmin mutations in pediatric acute myeloid leukemia with normal karyotype: a study of the Japanese Childhood AML Cooperative Study Group. Leukemia 2007; 21:1307. (Pubitemid 46831822)
42. Laughlin TS, Becker MW, Liesveld JL, et al. Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia. J Mol Diagn 2008; 10:338-345. (Pubitemid 352019120)
43. Ottone T, Ammatuna E, Lavorgna S, et al. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn 2008; 10:212-216. (Pubitemid 351692163)
44. Szankasi P, Jama M, Bahler DW. A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis. J Mol Diagn 2008; 10:236-241. (Pubitemid 351692166)
45. Wertheim G, Bagg A. Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies. J Mol Diagn 2008; 10:198-202. (Pubitemid 351692161)
46. Huang Q, Chen W, Gaal KK, et al. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AMLwith normal cytogenetics. Br J Haematol 2008; 142:489-492.
47. Dvorakova D, Lengerova M, Pospisilova J, et al. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations. Leukemia 2009; 23:793-796.
48. Ma W, Kantarjian H, Zhang X, et al. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomark 2009; 5:51-58.
49. Falini B, Lenze D, Hasserjian R, et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia 2007; 21:1566-1570. (Pubitemid 46965302)
50. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009. [Epub ahead of print]
51. Alblero E, Madeo D, Bolli N, et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon11 NPM1 mutation. Leukemia 2007; 21:1099-1103. (Pubitemid 46672090)
52. Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood 2006; 108:4146-4155.
53. Falini B, Martelll MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006; 108:1999-2005.
54. Konoplev S, Huang X, Drabkin HA, et al. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutations and is not predictive of prognosis. Cancer 2009. [Epub ahead of print]
55. Martelli MP, Manes N, Liso A, et al. A western blot assay for detecting mutant nucleophosmin (NPM1 ) proteins in acute myeloid leukaemia. Leukemia 2008; 22:2285-2288.
56. Oelschlaegel U, Koch S, Schaich M, et al. A rapid flow cytometric method for the detection of NPM1 mutated patients with acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts) 2008; 112:1490.
57. Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastlc syndrome (MDS). Blood 2009; 113:5250-5253.
58. Cilloni D, Messa F, Rosso V, et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NFkappaB in AML carrying NPM1 mutations. Leukemia 2008; 22:1234-1240. (Pubitemid 351833792)
59. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106:3733-3739.
60. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106:3740-3746. (Pubitemid 41739007)
61. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-1918.
62. Hollink IH, Zwaan CM, Zimmermann M, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML Leukemia 2009; 23:262-270.
63. Scholl S, Theuer C, Scheble V, et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 2008; 80:208-215. (Pubitemid 351253464)
64. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27:61-69.
65. Liso A, Colau D, Benmaamar R, et al. Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. Leukemia 2008; 22:424-426. (Pubitemid 351250548)
66. Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006; 20:1103-1108. (Pubitemid 43797304)
67. Chou WC, Tang JL, Wu SJ, of et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007; 21:998-1004.
68. Barragan E, Pajuelo JC, Ballester S, et al. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clin Chim Acta 2008; 395:120-123.
69. Bacher U, Badbaran A, Fehse B, et al. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009; 37:135142.
70. Grisendi S, Mecucci C, Falini B, et al. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6:493-505.
71. Maggi LB Jr, Kuchenruether M, Dadey DY, et al. Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome. Mol Cell Biol 2008; 28:7050-7065.
72. Falinl B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML Blood 2006; 107:4514-4523.
73. Grummitt CG, Townsley FM, Johnson CM, et al. Structural consequences of nucleophosmin mutations in acute myeloid leukemia. J Biol Chem 2008; 283:23326-23332.
74. Bolli N, Nicoletti I, De Marco MF, et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res 2007; 67:6230-6237. (Pubitemid 47037504)
75. Dong X, Biswas A, Suel KE, et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009; 458:1136-1141.
76. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009; 69:510-517.
77. Scaloni F, Gianni S, Federlci L, et al. Folding mechanism of the C-terminal domain of nucleophosmin: residual structure in the denatured state and its pathophysiological significance. FASEB J 2009; 23:2360-2365.
78. Amin MA, Matsunaga S, Uchiyama S, et al. Nucleophosmin is required for chromosome congression, proper mitotic spindle formation, and kinetochore-microtubule attachment in HeLa cells. FEBS Lett 2008; 582:3839-3844.
79. Leuenroth SJ, Crews CM. Triptolide-induced transcriptional arrest is associated with changes in nuclear substructure. Cancer Res 2008; 68:5257-5266.
80. Qi W, Shakalya K, Stejskal A, et al. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene 2008; 27:4210-4220. (Pubitemid 351969907)
81. Perera Y, Farina HG, Gil J, et al. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. Mol Cancer Ther 2009. [Epub ahead of print].
82. Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005; 19:1760-1767.
83. Schlenk RF, Dohner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retlnoio acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009; 94:54-60.
84. GaleR, Hills R, Green C, et al. The impact of FLT3-ITD and NPM1 mutational status on the outcome of ATRA therapy in patients with non-APL AML: results of the UK MRC12 trial. Blood (ASH Annual Meeting Abstracts) 2008; 112:554.
85. Martelli MP, Pettirossi V, Manes N, et al. Selective silencing of the NPM1 mutant protein and apoptosis induction upon ATRA in vitro treatment of AML cells carrying NPM1 mutations. Blood (ASH Annual Meeting Abstracts) 2007; 110:868.